

- Lymph-glands, inguinal, metastases in, from squamous-celled carcinoma of cervix, 399
- lumbar, metastases in, from sarcoma of uterus, 222
- mediastinal, metastases in, from adenocarcinoma of uterus, 414
- mesenteric, metastases in, from squamous-celled carcinoma of cervix, 399
- sarcoma of, secondary to sarcoma of uterus, 234
- pelvic, metastases in, from squamous-celled carcinoma of cervix, 399
- pericardial, metastases in, from adenocarcinoma of uterus, 405
- peripancreatic, sarcoma of, 234
- Lymph-spaces, dilated, in broad ligament, in myoma, 355
- MALFORMATIONS** of uterus, myoma associated with, 155, 157
- Mania, acute, after abdominal hysteromyomectomy, 661
- Mediastinal lymph-glands, metastases in, from adenocarcinoma of uterus, 414
- Menstrual flow, retained, enlargement of uterus due to, 485
- history in myoma cases, 443
- Menstruation in differential diagnosis of myoma and pregnancy, 467
- influence of myoma on, 443
- vicarious, after abdominal hysteromyomectomy, 605
- Mesenteric lymph-glands, sarcoma of, secondary to sarcoma of uterus, 234
- vessels affording blood-supply to parasitic myoma, 39
- Mesentery, abnormally long, in myoma cases, 464
- calcareous nodules in, with myoma, 464
- metastases in, from adenocarcinoma of uterus, 408
- from squamous-celled carcinoma of cervix, 399
- sarcoma of, secondary to sarcoma of uterus, 234
- Metastases, abdominal, with myosarcoma of uterus, 200
- from adenocarcinoma of uterus to bronchial lymph-glands, 405
- to cervical lymph-glands, 405
- to inguinal lymph-glands, 405
- to omentum, 405
- to pericardial lymph-glands, 405
- to peritoneum, 405
- Metastases from sarcoma of uterus to peripancreatic lymph-glands, 234
- in adrenal body from adenocarcinoma of uterus, 408
- in bronchial lymph-glands from squamous-celled carcinoma of cervix, 399
- in inguinal lymph-glands from squamous-celled carcinoma of cervix, 399
- in intestine, secondary to sarcoma of uterus, 234
- in liver from adenocarcinoma of uterus, 234, 408
- in lumbar glands from sarcoma of uterus, 222
- in lungs from adenocarcinoma of body of uterus, 408
- from squamous-celled carcinoma of cervix, 399
- secondary to sarcoma of uterus, 195, 234
- in mediastinal lymph-glands from adenocarcinoma of uterus, 414
- in mesenteric lymph-glands, from squamous-celled carcinoma of cervix, 399
- secondary to sarcoma of uterus, 234
- in mesentery, from adenocarcinoma of uterus, 408
- secondary to sarcoma of uterus, 234
- in omentum, 499
- from adenocarcinoma of uterus, 408
- secondary to sarcoma of uterus, 234
- in pancreas, from adenocarcinoma of uterus, 408
- in peritoneum, from adenocarcinoma of uterus, 408
- from squamous-celled carcinoma of cervix, 399
- secondary to sarcoma of uterus, 195, 234
- in pleura, from adenocarcinoma of uterus, 408, 414
- from squamous-celled carcinoma of cervix, 399
- secondary to sarcoma of uterus, 234
- in spleen, from adenocarcinoma of body of uterus, 414
- in stomach, secondary to sarcoma of uterus, 234
- of chordæ tendineæ of tricuspid valve following sarcoma of uterus, 222
- Miscarriages in myoma cases, 458
- Mobility of myomata, 444
- importance of determining, before operation, 445
- Mole, hydatid, myoma and, differentiation, 480
- Mortality. *See Death.*
- Mucosa, cervical, changes in, in myoma cases, 297, 298, 302